Circular RNA CircZNF644 Facilitates Circulating Follicular Helper T Cells Response in Patients with Graves' Disease.

Publisher: Hindawi Publishing Corporation Country of Publication: Egypt NLM ID: 101627166 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-7156 (Electronic) Linking ISSN: 23147156 NLM ISO Abbreviation: J Immunol Res Subsets: MEDLINE

Original Publication: Cairo, Egypt : Hindawi Publishing Corporation, [2014]-

Graves Disease*/genetics ; Graves Disease*/immunology ; RNA, Circular*/genetics ; T Follicular Helper Cells*/immunology ; MicroRNAs*/genetics; Humans ; Male ; Female ; Adult ; Middle Aged ; Autoantibodies/immunology ; Autoantibodies/blood ; Inducible T-Cell Co-Stimulator Protein/metabolism ; Inducible T-Cell Co-Stimulator Protein/genetics ; Interleukins/genetics ; Interleukins/metabolism ; Leukocytes, Mononuclear/immunology ; Leukocytes, Mononuclear/metabolism ; Gene Expression Regulation

Aberrant accumulation of circulating follicular helper T cells (cTfh) has been found in the peripheral blood mononuclear cells (PBMCs) of Graves' disease (GD) patients. However, the underlying mechanism that contributes to the imbalance of cTfh cells remains unknown. Previously, studies described a GD-related circular RNAs (circRNAs)-circZNF644 that might be associated with cTfh cells. This study aimed to investigate the role of circZNF644 on cTfh cells in GD patients. Here, we found that circZNF644 was highly stable expression in the PBMCs of GD patients, which was positively correlated with the serum levels of TSH receptor autoantibodies (TRAb). Knockdown of circZNF644 caused a reduction of the proportion of cTfh cells in vitro. Mechanistically, circZNF644 served as a ceRNA for miR-29a-3p to promote ICOS expression, resulting in increased cTfh cells. In the PBMCs of GD patients, circZNF644 expression was positively correlated with ICOS expression and the percentage of cTfh cells, but negatively related to miR-29a-3p expression. Additionally, a strong relationship between circZNF644 and IL-21 was revealed in GD patients, and silencing of circZNF644 inhibited IL-21 expression. Our study elucidated that elevated expression of circZNF644 is a key feature in the development of GD and may contribute to the pathogenic role of cTfh cells in GD.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2024 Yingzhao Liu et al.)

J Autoimmun. 2024 Jun;146:103235. (PMID: 38696926)
N Engl J Med. 2016 Oct 20;375(16):1552-1565. (PMID: 27797318)
Nat Rev Immunol. 2022 Sep;22(9):567-575. (PMID: 35277664)
Mol Cancer. 2020 Dec 14;19(1):172. (PMID: 33317550)
Front Immunol. 2021 Mar 26;12:641013. (PMID: 33841422)
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20371-6. (PMID: 19915142)
Thyroid. 2010 Feb;20(2):213-6. (PMID: 20151830)
EBioMedicine. 2018 Aug;34:267-274. (PMID: 30078734)
Mol Cancer. 2022 May 5;21(1):108. (PMID: 35513849)
Nat Rev Genet. 2019 Nov;20(11):675-691. (PMID: 31395983)
Immunity. 2011 Jan 28;34(1):108-21. (PMID: 21215658)
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101387. (PMID: 32107168)
Immunol Res. 2023 Apr;71(2):173-184. (PMID: 36322282)
Int J Mol Sci. 2023 Apr 06;24(7):. (PMID: 37047805)
Semin Nucl Med. 2024 Mar;54(2):219-236. (PMID: 38044176)
Neurol Neuroimmunol Neuroinflamm. 2021 Jan 12;8(2):. (PMID: 33436376)
Immunol Rev. 2019 Mar;288(1):97-111. (PMID: 30874343)
Methods Mol Biol. 2022;2380:29-39. (PMID: 34802119)
Clin Transl Med. 2022 Dec;12(12):e1117. (PMID: 36447054)
Annu Rev Immunol. 2011;29:621-63. (PMID: 21314428)
J Immunol Res. 2022 Feb 02;2022:4075522. (PMID: 35224111)
Am J Pathol. 2001 Sep;159(3):861-73. (PMID: 11549579)
J Allergy Clin Immunol. 2018 Apr;141(4):1202-1207. (PMID: 29074454)
Lancet. 2012 Mar 24;379(9821):1155-66. (PMID: 22394559)
Annu Rev Immunol. 2012;30:429-57. (PMID: 22224772)
J Clin Endocrinol Metab. 2014 Nov;99(11):4060-1. (PMID: 25210884)
J Clin Endocrinol Metab. 2012 Mar;97(3):943-50. (PMID: 22188745)
Front Immunol. 2022 May 24;13:885896. (PMID: 35686126)
Immunol Rev. 2019 Mar;288(1):85-96. (PMID: 30874350)
Nat Rev Dis Primers. 2020 Jul 2;6(1):52. (PMID: 32616746)
Cell Res. 2017 Dec;27(12):1401-1402. (PMID: 29086764)
J Bioenerg Biomembr. 2022 Aug;54(4):215-226. (PMID: 35976517)
Nat Rev Endocrinol. 2013 Dec;9(12):724-34. (PMID: 24126481)
Nature. 1999 Jan 21;397(6716):263-6. (PMID: 9930702)
J Autoimmun. 2023 Jan;134:102976. (PMID: 36525939)
Environ Toxicol. 2022 Dec;37(12):2855-2864. (PMID: 36052886)
Sci Rep. 2022 Oct 7;12(1):16880. (PMID: 36207336)
Theranostics. 2019 Jan 1;9(2):588-607. (PMID: 30809295)
EMBO J. 2019 Aug 15;38(16):e100836. (PMID: 31343080)
Clin Sci (Lond). 2020 Jan 31;134(2):139-154. (PMID: 31930399)

0 (RNA, Circular)
0 (MicroRNAs)
0 (Autoantibodies)
0 (Inducible T-Cell Co-Stimulator Protein)
MKM3CA6LT1 (interleukin-21)
0 (Interleukins)
0 (ICOS protein, human)

Date Created: 20240705 Date Completed: 20240705 Latest Revision: 20240706

20240706

PMC11223900

10.1155/2024/9527268

38966668